Lysosomal ceroid depletion by drugs: therapeutic implications for a hereditary neurodegenerative disease of childhood
- PMID: 11283676
- DOI: 10.1038/86554
Lysosomal ceroid depletion by drugs: therapeutic implications for a hereditary neurodegenerative disease of childhood
Abstract
Neuronal ceroid lipofuscinoses (NCLs) are the most common hereditary neurodegenerative diseases of childhood. The infantile form, INCL, is caused by lysosomal palmitoyl-protein thioesterase (PPT) deficiency, which impairs the cleavage of thioester linkages in palmitoylated proteins, preventing their hydrolysis by lysosomal proteinases. Consequent accumulation of these lipid-modified proteins (constituents of ceroid) in lysosomes leads to INCL. Because thioester linkages are susceptible to nucleophilic attack, drugs with this property may have therapeutic potential for INCL. We report here that two such drugs, phosphocysteamine and N-acetylcysteine, disrupt thioester linkages in a model thioester compound, [14C]palmitoyl approximately CoA. Most importantly, in lymphoblasts derived from INCL patients, phosphocysteamine, a known lysosomotrophic drug, mediates the depletion of lysosomal ceroids, prevents their re-accumulation and inhibits apoptosis. Our results define a novel pharmacological approach to lysosomal ceroid depletion and raise the possibility that nucleophilic drugs such as phosphocysteamine hold therapeutic potential for INCL.
Similar articles
-
Palmitoyl-protein thioesterase and the molecular pathogenesis of infantile neuronal ceroid lipofuscinosis.Neuropediatrics. 1997 Feb;28(1):27-30. doi: 10.1055/s-2007-973661. Neuropediatrics. 1997. PMID: 9151316
-
Neuroprotection and lifespan extension in Ppt1(-/-) mice by NtBuHA: therapeutic implications for INCL.Nat Neurosci. 2013 Nov;16(11):1608-17. doi: 10.1038/nn.3526. Epub 2013 Sep 22. Nat Neurosci. 2013. PMID: 24056696 Free PMC article.
-
First-trimester diagnosis of infantile neuronal ceroid lipofuscinosis (INCL) using PPT enzyme assay and CLN1 mutation analysis.Prenat Diagn. 1999 Jun;19(6):559-62. Prenat Diagn. 1999. PMID: 10416973
-
Sphingolipid activator proteins (SAPs) in neuronal ceroid lipofuscinoses (NCL).Neuropediatrics. 1997 Feb;28(1):49-52. doi: 10.1055/s-2007-973667. Neuropediatrics. 1997. PMID: 9151322 Review.
-
The mechanism and functional roles of protein palmitoylation in the nervous system.Neuropediatrics. 1997 Feb;28(1):23-6. doi: 10.1055/s-2007-973660. Neuropediatrics. 1997. PMID: 9151315 Review.
Cited by
-
Stable isotope gas chromatography-tandem mass spectrometry determination of aminoethylcysteine ketimine decarboxylated dimer in biological samples.Anal Biochem. 2012 Nov 1;430(1):4-15. doi: 10.1016/j.ab.2012.07.022. Epub 2012 Jul 31. Anal Biochem. 2012. PMID: 22858756 Free PMC article.
-
Patient-Derived Induced Pluripotent Stem Cell Models for Phenotypic Screening in the Neuronal Ceroid Lipofuscinoses.Molecules. 2021 Oct 15;26(20):6235. doi: 10.3390/molecules26206235. Molecules. 2021. PMID: 34684815 Free PMC article. Review.
-
Lysosomal storage diseases--the horizon expands.Nat Rev Neurol. 2013 Oct;9(10):583-98. doi: 10.1038/nrneurol.2013.163. Epub 2013 Aug 13. Nat Rev Neurol. 2013. PMID: 23938739 Review.
-
Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses.CNS Drugs. 2019 Apr;33(4):315-325. doi: 10.1007/s40263-019-00620-8. CNS Drugs. 2019. PMID: 30877620 Free PMC article. Review.
-
Evaluation of disease progression in INCL by MR spectroscopy.Ann Clin Transl Neurol. 2015 Aug;2(8):797-809. doi: 10.1002/acn3.222. Epub 2015 Jul 1. Ann Clin Transl Neurol. 2015. PMID: 26339674 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical